Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2007 1
2008 3
2009 2
2011 4
2012 13
2013 13
2014 16
2015 24
2016 23
2017 50
2018 50
2019 54
2020 94
2021 91
2022 6
Text availability
Article attribute
Article type
Publication date

Search Results

401 results
Results by year
Filters applied: . Clear all
Page 1
Targeting Sirtuin 1 signaling pathway by ginsenosides.
Lou T, Huang Q, Su H, Zhao D, Li X. Lou T, et al. Among authors: su h. J Ethnopharmacol. 2021 Mar 25;268:113657. doi: 10.1016/j.jep.2020.113657. Epub 2020 Dec 1. J Ethnopharmacol. 2021. PMID: 33276056 Review.
Development and evaluation of a rapid CRISPR-based diagnostic for COVID-19.
Hou T, Zeng W, Yang M, Chen W, Ren L, Ai J, Wu J, Liao Y, Gou X, Li Y, Wang X, Su H, Gu B, Wang J, Xu T. Hou T, et al. Among authors: su h. PLoS Pathog. 2020 Aug 27;16(8):e1008705. doi: 10.1371/journal.ppat.1008705. eCollection 2020 Aug. PLoS Pathog. 2020. PMID: 32853291 Free PMC article.
Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape.
Ku Z, Xie X, Davidson E, Ye X, Su H, Menachery VD, Li Y, Yuan Z, Zhang X, Muruato AE, I Escuer AG, Tyrell B, Doolan K, Doranz BJ, Wrapp D, Bates PF, McLellan JS, Weiss SR, Zhang N, Shi PY, An Z. Ku Z, et al. Among authors: su h. Nat Commun. 2021 Jan 20;12(1):469. doi: 10.1038/s41467-020-20789-7. Nat Commun. 2021. PMID: 33473140 Free PMC article.
Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice.
Dash PK, Kaminski R, Bella R, Su H, Mathews S, Ahooyi TM, Chen C, Mancuso P, Sariyer R, Ferrante P, Donadoni M, Robinson JA, Sillman B, Lin Z, Hilaire JR, Banoub M, Elango M, Gautam N, Mosley RL, Poluektova LY, McMillan J, Bade AN, Gorantla S, Sariyer IK, Burdo TH, Young WB, Amini S, Gordon J, Jacobson JM, Edagwa B, Khalili K, Gendelman HE. Dash PK, et al. Among authors: su h. Nat Commun. 2019 Jul 2;10(1):2753. doi: 10.1038/s41467-019-10366-y. Nat Commun. 2019. PMID: 31266936 Free PMC article.
Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002).
Shi Y, Wu J, Wang Z, Zhang L, Wang Z, Zhang M, Cen H, Peng Z, Li Y, Fan L, Guo Y, Ma L, Cui J, Gao Y, Yang H, Zhang H, Wang L, Zhang W, Zhang H, Xie L, Jiang M, Zhou H, Shuang Y, Su H, Ke X, Jin C, Du X, Du X, Liu L, Xi Y, Ge Z, Feng R, Zhang Y, Zhou S, Xie F, Wang Q. Shi Y, et al. Among authors: su h. J Hematol Oncol. 2021 Jan 12;14(1):12. doi: 10.1186/s13045-021-01033-1. J Hematol Oncol. 2021. PMID: 33436023 Free PMC article. Clinical Trial.
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
Shi Y, Jia B, Xu W, Li W, Liu T, Liu P, Zhao W, Zhang H, Sun X, Yang H, Zhang X, Jin J, Jin Z, Li Z, Qiu L, Dong M, Huang X, Luo Y, Wang X, Wang X, Wu J, Xu J, Yi P, Zhou J, He H, Liu L, Shen J, Tang X, Wang J, Yang J, Zeng Q, Zhang Z, Cai Z, Chen X, Ding K, Hou M, Huang H, Li X, Liang R, Liu Q, Song Y, Su H, Gao Y, Liu L, Luo J, Su L, Sun Z, Tan H, Wang H, Wang J, Wang S, Zhang H, Zhang X, Zhou D, Bai O, Wu G, Zhang L, Zhang Y. Shi Y, et al. Among authors: su h. J Hematol Oncol. 2017 Mar 15;10(1):69. doi: 10.1186/s13045-017-0439-6. J Hematol Oncol. 2017. PMID: 28298231 Free PMC article.
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial.
Shi Y, Su H, Song Y, Jiang W, Sun X, Qian W, Zhang W, Gao Y, Jin Z, Zhou J, Jin C, Zou L, Qiu L, Li W, Yang J, Hou M, Zeng S, Zhang Q, Hu J, Zhou H, Xiong Y, Liu P. Shi Y, et al. Among authors: su h. Lancet Haematol. 2019 Jan;6(1):e12-e19. doi: 10.1016/S2352-3026(18)30192-3. Lancet Haematol. 2019. PMID: 30612710 Clinical Trial.
401 results